Please assess the completion status of the following clinical trial:

Trial Title: Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Enrolled on protocol IBCSG-1-98~  * Currently receiving (i.e., have not yet completed) 5 years of treatment with tamoxifen or letrozole and expected to receive ≥ 6 months of additional treatment on protocol IBCSG-1-98~* No recurrent breast cancer or second primary cancer~* No known bone disease (including osteomalacia or osteogenesis imperfecta)~* Hormone receptor status~  * Estrogen and/or progesterone receptor positive tumor~PATIENT CHARACTERISTICS:~* Female~* Postmenopausal~* No uncontrolled thyroid or parathyroid disease, Cushing's disease, or other pituitary diseases~* No malabsorption syndrome or clinically relevant vitamin D deficiency~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 1 year since prior and no concurrent anticonvulsants~* More than 6 months since prior and no concurrent corticosteroids at doses \> the equivalent of 5 mg/day of prednisone for \> 2 weeks total~* No prior or concurrent sodium fluoride at daily doses ≥ 5 mg/day for \> 1 month~* More than 12 months since prior and no concurrent anabolic steroids~* More than 6 months since any prior drug for the prevention of osteoporosis (excluding calcium or cholecalciferol \[vitamin D\])~* Concurrent warfarin allowed provided duration of treatment is no more than 4 weeks

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tamoxifen and no bone fracture (Type: EXPERIMENTAL): Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have not had a bone fracture.
- Letrozole and no bone fracture (Type: EXPERIMENTAL): Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have not had a bone fracture.
- Tamoxifen and bone fracture (Type: EXPERIMENTAL): Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have had a bone fracture.
- Letrozole and bone fracture (Type: EXPERIMENTAL): Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have had a bone fracture.

Based on this trial design, predict the completion outcome and termination type (if applicable).